Patent Grant
11439506
This document relates to prosthetic heart valves, such as prosthetic mitral valves that can be implanted using transcatheter techniques.
The long-term clinical effect of valve regurgitation is recognized as a significant contributor to cardiovascular related morbidity and mortality. Thus, for many therapies intended to treat the mitral valve, one primary goal is to significantly reduce or eliminate regurgitation. By eliminating the regurgitation at the mitral valve, the destructive volume overload effects on the left ventricle can be attenuated. The volume overload of mitral regurgitation (MR) relates to the excessive kinetic energy required during isotonic contraction to generate overall stroke volume in an attempt to maintain forward stroke volume and cardiac output. It also relates to the pressure potential energy dissipation of the leaking valve during the most energy-consuming portion of the cardiac cycle, isovolumetric contraction. Additionally, therapies for MR reduction can have the effect of reducing the elevated pressures in the left atrium and pulmonary vasculature reducing pulmonary edema (congestion) and shortness of breath symptomatology. Such therapies for MR reduction may also have a positive effect on the filling profile of the left ventricle (LV) and the restrictive LV physiology that can result with MR. These pathophysiologic issues indicate the potential benefits of MR therapy, but also indicate the complexity of the system and the need for a therapy to focus beyond the MR level or grade.
Some therapies for treating MR may worsen other (non-MR) existing pathologic conditions or create new pathologic conditions. One of the conditions to be managed is mitral stenosis or creation of an inflow gradient. That is, if a prosthetic valve system is used that does not allow for sufficient LV inflow without elevated filling pressures, then some benefits of MR reduction may be dissipated or lost. An additional condition to be managed is left ventricular outflow tract (LVOT) obstruction or creation of high LVOT pressure gradients. That is, if a prosthetic valve system is used that does significantly obstructs the LVOT, then some benefits of MR reduction may be dissipated or lost. Also, if the procedure results in damage to atrial tissue at surgery, it can increase the likelihood of the negative physiologic effect of atrial fibrillation. Further, some prosthetic valve systems may increase the risk of higher LV wall stress through an increase in LV size (LV geometry). Due to the integral relationship of the mitral valve with LV geometry through the papillary and chordal apparatus, LV wall stress levels can be directly affected resulting in alterations of LV filling and contraction mechanics. Accordingly, in some circumstances, a prosthetic valve system that worsens the geometry of the LV can counter the benefits of MR reduction because of the alteration of contractile physiology.
This document describes prosthetic heart valves, such as prosthetic mitral valves that can be implanted using transcatheter techniques. For example, some embodiments of a transcatheter mitral valve delivery system and method described herein can be deployed to interface and anchor in cooperation with the native anatomical structures of a mitral valve. In addition, this document describes prosthetic heart valve systems that interface with native mitral valve structures to create a fluid seal, thereby minimizing MR and paravalvular leaks after implantation. Further, this document describes prosthetic heart valve systems and techniques that, in particular embodiments, are configured to manage blood flow through the left ventricular outflow tract (LVOT) and to thereby reduce the risk of full or partial blockages of the LVOT. In addition, some embodiments of the prosthetic heart valve systems and techniques described herein may be configured to reduce the risk of interference between the prosthetic valves and chordae tendineae of the native mitral valve leaflets, which can advantageously facilitate or preserve the geometry of the LV.
Particular embodiments described herein include a mitral valve replacement system for a heart. The system may include an expandable anchor assembly configured to implant at a native mitral valve, and the expandable anchor assembly may include a first expandable frame that is adjustable from a delivery condition to an expanded condition. The system may also include a first delivery sheath device having a distal end insertable into a left atrium and being configured to express the anchor assembly out from the distal end such that the anchor assembly expands within the left atrium to the expanded condition. Optionally, the system may further include a pusher instrument releasably attachable to the expandable anchor frame and being configured to longitudinally advance the anchor assembly within the left atrium towards an annulus of the native mitral valve while the anchor assembly is in the expanded condition. Also, the system may include an artificial valve assembly comprising a second expandable frame that is adjustable from a compressed condition to a deployed condition to selectively engage with the anchor assembly while the anchor assembly is in the expanded condition.
Some embodiments described herein include a method for deploying a prosthetic mitral valve system within a native mitral valve of a patient. The method may include navigating a first delivery sheath within the patient such that a distal end of the first delivery sheath is positioned within a left atrium. The method may also include expressing an anchor assembly of the prosthetic heart valve system from the distal end of the first delivery sheath such that the anchor assembly at least partially expands while located within the left atrium. Further, the method may include, after expressing the anchor assembly within the left atrium, moving the anchor assembly towards an annulus of the native mitral valve.
Various embodiments described herein include a prosthetic mitral valve system. The system may include a valve assembly, which may include a frame member defining an outer profile and an interior frame member space, and an occluder disposed within the interior frame member space. The occluder may have an open configuration and a closed configuration. The frame member comprises a proximal end frame portion and a distal end frame portion. Optionally, an outer periphery of the distal end frame portion may include a generally flat region and a generally round region, and at least some portions of the generally flat region may extend toward the interior frame member space.
Particular embodiments described herein include a method of using a prosthetic mitral valve system. The method may include advancing a valve assembly of the prosthetic mitral valve system toward an annulus of a native mitral valve. Optionally, the valve assembly may include a frame member defining an outer profile and an interior frame member space, and occluder disposed within the interior frame member space. The frame member may include a proximal end frame portion and a distal end frame portion. An outer periphery of the distal end frame portion may optionally include a generally flat region and a generally round region, and at least some portions of the generally flat region extend toward the interior frame member space. The method may also include anchoring the valve assembly at the native mitral valve such that the generally flat region is adjacent to an anterior native leaflet of the native mitral valve.
Some embodiments described herein include a prosthetic mitral valve system that is implantable at a native mitral valve. The prosthetic mitral valve system may include an anchor assembly defining an interior anchor assembly space and longitudinal axis. The anchor assembly may include an expandable anchor frame including a hub and a sub-annular support arm extending from the hub. The sub-annular support arm may extend to an anchor foot having a surface configured for engagement with a sub-annular gutter of the native mitral valve. The system may further include a valve assembly that includes an expandable valve frame defining an outer profile and an interior frame member space, and an occluder disposed within the interior frame member space. The valve assembly may be releasably engageable with the anchor assembly within the interior anchor assembly space. Optionally, a distance measured parallel to the longitudinal axis from a distal-most end of the anchor assembly to the surface is at least 14 millimeters.
Various embodiments described herein include a method of using a prosthetic mitral valve system. The method may include advancing an anchor assembly of the prosthetic mitral valve system toward an annulus of a native mitral valve. The anchor assembly may an interior anchor assembly space and longitudinal axis, and the anchor assembly may include an expandable anchor frame including a hub and one or more sub-annular support arms extending from the hub. Each of the one or more sub-annular support arm may extend to an anchor foot configured to engage with a sub-annular gutter of the native mitral valve. The method may further include engaging the anchor assembly of the prosthetic mitral valve system with tissue proximate the native mitral valve such that each anchor foot is engaged with the sub-annular gutter, and (optionally) such that the hub is positioned distal of the distal-most area of coaptation between anterior and post leaflets of the native mitral valve.
Particular embodiments described herein include a method of sealing between a prosthetic mitral valve system and native leaflets of a mitral valve. The method may include anchoring an anchor assembly of the prosthetic mitral valve system with tissue proximate to an annulus of a native mitral valve. Optionally, the anchor assembly defines an interior anchor assembly space and longitudinal axis, and the anchor assembly may include an expandable anchor frame including a hub and one or more sub-annular support arms extending from the hub. Each of the one or more sub-annular support arm may extend to an anchor foot that engages with a sub-annular gutter of the native mitral valve. The method may further include delivering a valve assembly of the prosthetic mitral valve system to engage with the anchor assembly. Optionally, the valve assembly may include: an expandable valve frame defining an outer profile and an interior frame member space, a tissue layer disposed over at least a portion of the outer profile, and an occluder disposed within the interior frame member space. The tissue layer of the valve assembly can abut with native leaflets of the mitral valve while each anchor foot of the anchor assembly is engaged with the sub-annular gutter.
Some embodiments described herein include a prosthetic mitral valve system. The system may include an anchor assembly comprising an expandable anchor frame and a set of sub-annular anchor feet configured to engage with a sub-annular gutter of the native mitral valve. The system may further include a valve assembly that includes: an expandable valve frame defining an outer profile and an interior frame member space, a tissue layer disposed over at least a portion of the outer profile, and an occluder mounted within the interior frame member space. Optionally, an outwardly facing periphery of the tissue layer along the valve assembly is positioned to abut native leaflets of the mitral valve when the set of anchor feet of the anchor assembly is engaged with the sub-annular gutter.
Various embodiments described herein include a method for deploying a prosthetic mitral valve system within a native mitral valve of a patient. The method may comprise navigating a delivery sheath such that a distal end of the delivery sheath is positioned within a left atrium of the patient. Also, the method may include expressing, in the left atrium, an anchor assembly of the prosthetic mitral valve system. A distal pusher instrument may be releasably engaged with the anchor assembly. The method may further include engaging the anchor assembly with the native mitral valve while the distal pusher instrument remains engaged with the anchor assembly. The method may also include expressing, in the left atrium, a valve assembly of the prosthetic mitral valve system. Optionally, the valve assembly may slidably engaged with an exterior of the distal pusher instrument. The method may further include moving the valve assembly into an interior space defined by the anchor assembly. The moving may optionally include sliding the valve assembly along the exterior of the distal pusher catheter while the distal pusher catheter remains engaged with to the anchor assembly. The method may also include, after moving the valve assembly, mounting the valve assembly with the anchor assembly. Further, the method may include, after mounting the valve assembly, decoupling the distal pusher instrument from the anchor assembly.
Particular embodiments described herein include an implantable medical device delivery system. The system may include a first deflectable catheter defining a first lumen therethrough, and a distal end portion of the first deflectable catheter may be controllably laterally deflectable. The system may also include a first device delivery sheath slidably disposable within the first lumen, and the first device delivery sheath may define a second lumen therethrough. The system may further include a first device control sheath slidably disposable within the second lumen, and the first device control sheath may define a third lumen therethrough and one or more first device control wire lumens. The system may also include a second deflectable catheter slidably disposable within the third lumen, and the second deflectable catheter may define a fourth lumen therethrough. A distal end portion of the second deflectable catheter may be controllably laterally deflectable. The system may further include a device pusher catheter slidably disposable within the fourth lumen, and the device pusher catheter may define a fifth lumen therethrough. A distal end portion of the device pusher catheter may be configured to releasably couple with a first implantable medical device.
Some embodiments described herein include a method for deploying a prosthetic mitral valve system within a native mitral valve of a patient. The method may include expanding an anchor assembly of the prosthetic heart valve system within a left atrium, while the anchor assembly is releasably secured to a first delivery catheter, such that the anchor assembly at least partially expands while located within the left atrium. The method may optionally include, after expressing the anchor assembly within the left atrium, panning or rotating the anchor assembly within the left atrium by articulating a tip portion of the first delivery catheter.
Various embodiments described herein include a method for deploying a prosthetic mitral valve system within a native mitral valve of a patient. The method may include expressing a valve assembly of the prosthetic heart valve system within a left atrium, while the valve assembly is releasably secured to a valve delivery catheter, such that the valve assembly at least partially expands while located within the left atrium. The method may optionally include, after expressing the valve assembly within the left atrium, panning or rotating the valve assembly within the left atrium by articulating a tip portion of the valve delivery catheter.
Some or all of the embodiments described herein may provide one or more of the following advantages. First, some embodiments of the prosthetic mitral valve systems provided herein can be used in a completely percutaneous/transcatheter mitral replacement procedure that is safe, reliable, and repeatable by surgeons of a variety of different skill levels. For example, in some implementations the prosthetic mitral valve system can establish a reliable and consistent anchor/substrate to which the valve/occluder structure subsequently engages. Thus, the prosthetic mitral valve system can be specifically designed to make use of the geometry/mechanics of the native mitral valve to create sufficient holding capability. In one particular aspect, the anatomical gutter found below a native mitral valve annulus can be utilized as a site for anchoring the prosthetic mitral valve system, yet the anchoring structure can be deployed in a matter that maintains native leaflet function of the mitral valve, thereby providing the ability to completely separate and stage the implantation of the components of the prosthetic mitral valve system. Accordingly, some embodiments of the prosthetic mitral valve systems described herein are configured to be implanted in a reliable, repeatable, and simplified procedure that is broadly applicable to a variety of patients and physicians, while also employing a significantly less invasive method.
Second, some embodiments of the prosthetic mitral valve systems described herein facilitate effective long lasting MR reduction without creating negative physiologic consequences to the cardiopulmonary system (heart, lungs, peripheral vasculature) including stenosis, LV wall stress, and atrial fibrillation. Also, the system may provide a safe and durable anchoring effect at the native mitral valve to provide an effective mitral regurgitation therapy as well as providing structures that provide sealing benefits and avoid significant impairment of the chordal interface of the native mitral valve leaflets.
Third, in particular embodiments, the prosthetic mitral valve system can be delivered to the native mitral valve using a technique in which an expandable frame of the anchor component is at least partially expanded in the left atrium prior to reaching the mitral valve location. As such, in addition to facilitating the delivery of the anchor, the heart surgeon or other user can visualize the expanded component (and its orientation) within the heart before it is advanced to the annulus of the mitral valve (thereby permitting the user the opportunity to laterally pivot (rotate, pan, re-orient) the expanded component prior to reaching the annulus).
Fourth, some embodiments of the prosthetic mitral valve systems described herein can be configured to partially extend into the left ventricle after implantation, yet may include a profile shape that is configured to reduce the likelihood of obstructing blood flow through the LVOT. Accordingly, even though some portions of the prosthetic mitral valve systems extend into the left atrium above the mitral valve annulus (supra-annular) and other portions extend into the left ventricle below the mitral valve annulus (sub-annular), the prosthetic mitral valve system is designed to account for the natural LVOT and thereby reduce the risk of full or partial blockages of the LVOT.
Fifth, in particular embodiments, the prosthetic mitral valve system can include two different expandable components (e.g., an anchor assembly and a valve assembly) that are separately delivered to the implantation site, and both components can abut and engage with native heart tissue at the mitral valve. For example, the first component (e.g., the anchor assembly) can be configured to engage with the heart tissue that is at or proximate to the annulus of the native mitral valve, and the second component (e.g., the valve assembly) can be configured to provide a seal interface with native valve leaflets of the mitral valve.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
Like reference symbols in the various drawings indicate like elements.
This disclosure describes embodiments of a prosthetic heart valve system, such as prosthetic mitral valve systems, and transcatheter systems and methods for implanting prosthetic heart valve systems. In some embodiments, the prosthetic mitral valve system can be deployed to interface and anchor in cooperation with the native anatomical structures of a mitral valve (and, optionally, in a manner that permits the continued natural function of the chordae tendineae of the native mitral valve leaflets even after the anchor component is deployed). As described herein, the prosthetic mitral valve system can be deployed in a manner that interfaces with native mitral valve structures to create a fluid seal, thereby minimizing MR and paravalvular leaks after implantation. As described in more detail below,
Referring to
The heart 10 (depicted in cross-section from a posterior perspective) includes a right atrium 12, a right ventricle 14, a left atrium 16, and a left ventricle 18. A tricuspid valve 13 separates the right atrium 12 from the right ventricle 14. A mitral valve 17 separates the left atrium 16 from the left ventricle 18. An atrial septum 15 separates the right atrium 12 from the left atrium 16. An inferior vena cava 11 is confluent with the right atrium 12. It should be understood that this depiction of the heart 10 is somewhat stylized. The same is true for
In the depicted embodiment, the delivery system 100 includes a guidewire 110, a primary deflectable catheter 120, and an anchor delivery sheath 130. Additional components of the delivery system 100 will be described further below. The anchor delivery sheath 130 is slidably (and rotationally) disposed within a lumen of the primary deflectable catheter 120. The guidewire 110 is slidably disposed within a lumen of the anchor delivery sheath 130. In this depiction, the anchor delivery sheath 130 has been partially extended relative to the primary deflectable catheter 120, allowing a flared portion 132 to expand outward, as described further below.
In the depicted implementation, the guidewire 110 is installed into the heart 10 prior to the other components of the delivery system 100. In some embodiments, the guidewire 110 has a diameter of about 0.035 inches (about 0.89 mm). In some embodiments, the guidewire 110 has a diameter in a range of about 0.032 inches to about 0.038 inches (about 0.8 mm to about 0.97 mm). In some embodiments, the guidewire 110 has a diameter smaller than 0.032 inches (about 0.80 mm) or larger than 0.038 inches (about 0.97 mm). In some embodiments, the guidewire 110 is made of materials such as, but not limited to, nitinol, stainless steel, high-tensile-strength stainless steel, and the like, and combinations thereof. The guidewire 110 may include various tip designs (e.g., J-tip, straight tip, etc.), tapers, coatings, covers, radiopaque (RO) markers, and other features.
In some implementations, the guidewire 110 is percutaneously inserted into a femoral vein of the patient. The guidewire 110 is routed to the inferior vena cava 11 and into the right atrium 12. After creating an opening in the atrial septum 15 (e.g., a trans-septal puncture of the fossa ovalis), the guidewire 110 is routed into the left atrium 16. Lastly, the guidewire 110 is routed through the mitral valve 17 and into the left ventricle 18. In some implementations, the guidewire 110 can be installed into the heart 10 along other anatomical pathways. The guidewire 110 thereafter serves as a rail over which other components of the delivery system 100 are passed.
In the depicted implementation, the primary deflectable catheter 120 is installed by pushing it over the guidewire 110. In some implementations, a dilator tip is used in conjunction with the primary deflectable catheter 120 as the primary deflectable catheter 120 is advanced over the guidewire 110. Alternatively, a balloon catheter could be used as the initial dilation means. After the distal end of the primary deflectable catheter 120 reaches the left atrium 16, the dilator tip can be withdrawn. In some embodiments, the distal end portion of the primary deflectable catheter 120 is steerable. Using steering, the distal end portion of the primary deflectable catheter 120 can be oriented as desired in order to navigate the patient's anatomy. For example, the primary deflectable catheter 120 can be angled within the right atrium 12 to navigate the primary deflectable catheter 120 from the inferior vena cava 11 to the atrial septum 15.
In some embodiments, the primary deflectable catheter 120 has an outer diameter of about 28 Fr (about 9.3 mm). In some embodiments, the primary deflectable catheter 120 has an outer diameter in the range of about 26 Fr to about 34 Fr (about 8.7 mm to about 11.3 mm). In some embodiments, the primary deflectable catheter 120 has an outer diameter in the range of about 20 Fr to about 28 Fr (about 6.7 mm to about 9.3 mm).
The primary deflectable catheter 120 can comprise a tubular polymeric or metallic material. For example, in some embodiments the primary deflectable catheter 120 can be made from polymeric materials such as, but not limited to, polytetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), HYTREL®, nylon, PICOFLEX®, PEBAX®, TECOFLEX®, and the like, and combinations thereof. In alternative embodiments, the primary deflectable catheter 120 can be made from metallic materials such as, but not limited to, nitinol, stainless steel, stainless steel alloys, titanium, titanium alloys, and the like, and combinations thereof. In some embodiments, the primary deflectable catheter 120 can be made from combinations of such polymeric and metallic materials (e.g., polymer layers with metal braid, coil reinforcement, stiffening members, and the like, and combinations thereof).
The example delivery system 100 also includes the anchor delivery sheath 130. In some implementations, after the primary deflectable catheter 120 is positioned with its distal end in the left atrium 16, the anchor delivery sheath 130 is installed into a lumen of the primary deflectable catheter 120 (over the guidewire 110) and advanced through the primary deflectable catheter 120. As described further below, in some embodiments the anchor delivery sheath 130 is preloaded with a prosthetic valve anchor assembly and other components of the delivery system 100.
In some embodiments, the anchor delivery sheath 130 can be made from the materials described above in reference to the primary deflectable catheter 120. In some embodiments, the anchor delivery sheath 130 has an outer diameter in the range of about 20 Fr to about 28 Fr (about 6.7 mm to about 9.3 mm). In some embodiments, the anchor delivery sheath 130 has an outer diameter in the range of about 14 Fr to about 24 Fr (about 4.7 mm to about 8.0 mm).
In the depicted embodiment, the anchor delivery sheath 130 includes a flared distal end portion 132. In some embodiments, no such flared distal end portion 132 is included. The flared distal end portion 132 can collapse to a lower profile when constrained within the primary deflectable catheter 120. When the flared distal end portion 132 is expressed from the primary deflectable catheter 120, the flared distal end portion 132 can self-expand to the flared shape. In some embodiments, the material of the flared distal end portion 132 includes pleats or folds, may be a continuous flared end or may be separated into sections such as flower pedals, and may include one or more resilient elements that bias the flared distal end portion 132 to assume the flared configuration in the absence of restraining forces (such as from containment within the primary deflectable catheter 120). The flared distal end portion 132 can be advantageous, for example, for recapturing the anchor assembly within the lumen of the anchor delivery sheath 130 after the anchor assembly has been expressed from the flared distal end portion 132.
In some embodiments, the maximum outer diameter of the flared distal end portion 132 is in a range of about 30 Fr to about 34 Fr (about 10.0 mm to about 11.3 mm). In some embodiments, the maximum outer diameter of the flared distal end portion 132 is in a range of about 32 Fr to about 44 Fr (about 10.7 mm to about 14.7 mm). In some embodiments, the maximum outer diameter of the flared distal end portion 132 is in a range of about 24 Fr to about 30 Fr (about 8.0 mm to about 10.0 mm). In some embodiments, the maximum outer diameter of the flared distal end portion 132 is less than about 24 Fr (about 8.0 mm) or greater than about 44 Fr (about 14.7 mm).
Referring to
In some implementations of delivery system 100, one or more of the proximal control sheath 140, the secondary deflectable catheter 150, the distal pusher catheter 160, and the anchor assembly 200 have been loaded into the anchor delivery sheath 130 prior to the advancement of the anchor delivery sheath 130 into the primary deflectable catheter 120 as shown in
The distal pusher catheter 160 is releasably coupled with a hub 210 of the anchor assembly 200. A proximal end of the anchor assembly 200 is also releasably coupled to the proximal control sheath 140 by one or more control wires 142. While the depicted embodiment includes one control wire 142, in some embodiments two, three, four, five, or more than five control wires are included.
Referring to
Referring again to
As the anchor assembly 200 emerges from the confines of the anchor delivery sheath 130, the anchor assembly 200 expands from a low-profile delivery configuration to a partially expanded configuration (as shown in
It should be understood that the prosthetic mitral valves provided herein are comprised of an anchor assembly 200 and a separable valve assembly (e.g., refer to
The staged implantation method of the prosthetic mitral valves provided herein is facilitated by the fact that when the anchor assembly 200 itself is implanted within the native mitral valve 17, the native mitral valve 17 continues to function essentially as before the implantation of the anchor assembly 200 without a significant impact on cardiovascular physiology. That is the case because, as described further below, the anchor assembly 200 interfaces and anchors within structural aspects of the native mitral valve 17 without substantially interfering with the leaflets or chordae tendineae of the native mitral valve 17.
Still referring to
Referring to
In preparation for engaging the anchor assembly 200 with the native mitral valve 17, the clinician operator may manipulate the radial size of the anchor frame 200 so that the anchor frame 200 can be passed through the native mitral valve 17 without damaging the native mitral valve 17. For example, the clinician can move the proximal control sheath 140 proximally in relation to the distal pusher catheter 160 to radially contract the anchor assembly 200. With the anchor assembly 200 radially contracted, the anchor frame 200 can be safely passed through the native mitral valve 17 without damaging the native mitral valve 17.
Referring to
In the depicted embodiment, the anchor assembly 200 includes four anchor feet: a left anterior foot 220a, a left posterior foot 220b, a right posterior foot 220c, and a right anterior foot 220d. In some embodiments, fewer or more anchor feet may be included (e.g., two, three, five, six, or more than six). In some embodiments, the anchor feet 220a, 220b, 220c, and 220d are portions of the anchor assembly 200 that are configured for contact with a sub-annular gutter 19 of the native mitral valve 17, without penetrating tissue of the native mitral valve 17. Accordingly, the anchor feet 220a, 220b, 220c, and 220d have atraumatic surfaces that are generally comparable to feet. However, in some embodiments one or more of the anchor feet 220a, 220b, 220c, and 220d are configured to penetrate tissue and may have anchor features such as barbs, coils, hooks, and the like.
In the arrangement of
Referring to
The anchor feet 220a, 220b, 220c, and 220d are positioned below the sub-annular gutter 19. In this position, the anchor feet 220a, 220b, 220c, and 220d are positioned under the systolic and diastolic excursions of the leaflets of the native mitral valve 17. In this orientation, the anchor feet 220a, 220b, 220c, and 220d can be aligned with the sub-annular gutter 19 in preparation for seating the anchor feet 220a, 220b, 220c, and 220d within the sub-annular gutter 19.
Referring to
Referring to
Referring to
The D-shaped annulus 28 defines the structure from which the anterior leaflet 20 and posterior leaflet 22 extend and articulate. The left and right fibrous trigones 134a and 134b are located near the left and right ends of the anterior leaflet 20 and generally adjacent the lateral and medial scallops 24a and 24c of the posterior leaflet 22. The sub-annular gutter 19 runs along the annulus 28 between the left and right fibrous trigones 134a and 134b along the posterior leaflet 22.
The regions at or near the high collagen annular trigones 134a and 134b can generally be relied upon to provide strong, stable anchoring locations. The muscle tissue in the regions at or near the trigones 134a and 134b also provides a good tissue ingrowth substrate for added stability and migration resistance of the anchor assembly 200. Therefore, the regions at or near the trigones 134a and 134b define a left anterior anchor zone 34a and a right anterior anchor zone 34b respectively. The left anterior anchor zone 34a and the right anterior anchor zone 34b provide advantageous target locations for placement of the left anterior foot 220a and the right anterior foot 220d respectively.
The depicted embodiment of the anchor assembly 200 also includes the left posterior foot 220b and the right posterior foot 220c. As previously described, the left posterior foot 220b and the right posterior foot 220c can also be advantageously positioned in the sub-annular gutter 19 in order to provide balanced and atraumatic coupling of the anchor assembly 200 to the native mitral valve 17. Therefore, a left posterior anchor zone 34b and a right anterior anchor zone 34c are defined in the sub-annular gutter 19. The left posterior anchor zone 34b and the right anterior anchor zone 34c can receive the left posterior foot 220b and the right posterior foot 220c respectively. In some implementations, the locations of the left posterior anchor zone 34b and the right anterior anchor zone 34c may vary from the depicted locations while still remaining within the sub-annular gutter 19. It should be understood that the depicted anchor assembly 200 is merely one non-limiting example of the anchor assemblies provided within the scope of this disclosure.
In some embodiments, the anchor assembly 200 includes supra-annular structures and sub-annular structures. For example, the sub-annular structures of the anchor assembly 200 include the aforementioned anchor feet 220a, 220b, 220c, and 220d, and the hub 210. In some embodiments, as described above, the hub 210 functions as a connection structure for the delivery system 100 (e.g., refer to
In some embodiments, such as the depicted embodiment, the supra-annular structures of the anchor assembly 200 include: a left anterior atrial holding feature 240a, a left posterior atrial holding feature 240b, a right posterior atrial holding feature 240c, and a right anterior atrial holding feature 240d; an anterior anchor arch 250a, a left anchor arch 250b, a posterior anchor arch 250c, and a right anchor arch 250d; and connection bridges 260. The anterior anchor arch 250a, left anchor arch 250b, posterior anchor arch 250c, and right anchor arch 250d are joined with each other to form an undulating supra-annular ring 250 that acts as a supra-annular structural element for the anchor assembly 200. As will be described further below, the supra-annular ring 250 also defines an opening to a space within the interior of the anchor assembly 200 that is configured to receive and engage with a valve assembly. The atrial holding features 240a, 240b, 240c, and 240d are configured to contact the shelf-like supra-annular tissue surface above the mitral valve annulus, and to thereby stabilize the anchor assembly 200 in supra-annular areas that are generally opposite of the anchor feet 220a, 220b, 220c, and 220d respectively.
In some embodiments, connection bridges 260 provide enhanced stability and fatigue resistance from vertically oriented forces on a companion artificial valve assembly when the valve (not shown) is closed and blocking pressurized blood during systole. The anchor assembly 200 can also include one or more holes 226 in frame portions adjacent the feet, which are additional control points for delivery and retrieval of the assembly, or could be used to secure a positional delivery frame.
In some embodiments, such as the depicted embodiment, the supra-annular structures and sub-annular structures of the anchor assembly 200 are interconnected by a lateral anterior inter-annular connection 270a, a lateral posterior inter-annular connection 270b, a medial posterior inter-annular connection 270c, and a medial anterior inter-annular connection 270d. For example, the lateral anterior inter-annular connection 270a connects the lateral anterior anchor foot 220a with the lateral anterior atrial holding feature 240a. In addition, the lateral anterior inter-annular connection 270a connects the lateral anterior anchor foot 220a with the anterior anchor arch 250a and the left anchor arch 250b. In the depicted embodiment, each of the other inter-annular connections 270b, 270c, and 270d interconnect portions of the supra-annular structures and sub-annular structures in manners analogous to that of the lateral anterior inter-annular connection 270a. For example, the lateral anterior inter-annular connection 270b connects the lateral anterior anchor foot 220b with the left anchor arch 250b and the posterior anchor arch 250c; the lateral anterior inter-annular connection 270c connects the lateral anterior anchor foot 220c with the posterior anchor arch 250c and the right anchor arch 250d; and the lateral anterior inter-annular connection 270d connects the lateral anterior anchor foot 220d with the right anchor arch 250d and the anterior anchor arch 250a.
In some embodiments, the elongate members of the anchor assembly 200 are formed from a single piece of precursor material (e.g., sheet or tube) that is cut, expanded, and connected to the hub 210. For example, some embodiments are fabricated from a tube that is laser-cut (or machined, chemically etched, water-jet cut, etc.) and then expanded and heat-set into its final expanded size and shape. In some embodiments, the anchor assembly 200 is created compositely from multiple elongate members (e.g., wires or cut members) that are joined together with the hub 210 and each other to form the anchor assembly 200.
The elongate members of the anchor assembly 200 can be comprised of various materials and combinations of materials. In some embodiments, nitinol (NiTi) is used as the material of the elongate members of the anchor assembly 200, but other materials such as stainless steel, L605 steel, polymers, MP35N steel, stainless steels, titanium, colbalt/chromium alloy, polymeric materials, Pyhnox, Elgiloy, or any other appropriate biocompatible material, and combinations thereof can be used. The super-elastic properties of NiTi make it a particularly good candidate material for the elongate members of the anchor assembly 200 because, for example, NiTi can be heat-set into a desired shape. That is, NiTi can be heat-set so that the anchor assembly 200 tends to self-expand into a desired shape when the anchor assembly 200 is unconstrained, such as when the anchor assembly 200 is deployed out from the anchor delivery sheath 130. A anchor assembly 200 made of NiTi, for example, may have a spring nature that allows the anchor assembly 200 to be elastically collapsed or “crushed” to a low-profile delivery configuration and then to reconfigure to the expanded configuration as shown in
In some embodiments, the diameter or width/thickness of one or more of the elongate members forming the anchor assembly 200 may be within a range of about 0.008″ to about 0.015″ (about 0.20 mm to about 0.40 mm), or about 0.009″ to about 0.030″ (about 0.23 mm to about 0.76 mm), or about 0.01″ to about 0.06″ (about 0.25 mm to about 1.52 mm), or about 0.02″ to about 0.10″ (about 0.51 mm to about 2.54 mm), or about 0.06″ to about 0.20″ (about 1.52 mm to about 5.08 mm). In some embodiments, the elongate members forming the anchor assembly 200 may have smaller or larger diameters or widths/thicknesses. In some embodiments, each of the elongate members forming the anchor assembly 200 has essentially the same diameter or width/thickness. In some embodiments, one or more of the elongate members forming the anchor assembly 200 has a different diameter or width/thickness than one or more of the other elongate members of the anchor assembly 200. In some embodiments, one or more portions of one or more of the elongate members forming the anchor assembly 200 may be tapered, widened, narrowed, curved, radiused, wavy, spiraled, angled, and/or otherwise non-linear and/or not consistent along the entire length of the elongate members of the anchor assembly 200. Such features and techniques can also be incorporated with the valve assemblies of the prosthetic mitral valves provided herein.
In some embodiments, the elongate members forming the anchor assembly 200 may vary in diameter, thickness and/or width so as to facilitate variations in the forces that are exerted by the anchor assembly 200 in specific regions thereof, to increase or decrease the flexibility of the anchor assembly 200 in certain regions, to enhance migration resistance, and/or to control the process of compression (crushability) in preparation for deployment and the process of expansion during deployment of the anchor assembly 200.
In some embodiments, one or more of the elongate members of the elongate members forming the anchor assembly 200 may have a circular cross-section. In some embodiments, one or more of the elongate members forming the anchor assembly 200 may have a rectangular cross-sectional shape, or another cross-sectional shape that is not rectangular. Examples of cross-sectional shapes that the elongate members forming the anchor assembly 200 may have include circular, C-shaped, square, ovular, rectangular, elliptical, triangular, D-shaped, trapezoidal, including irregular cross-sectional shapes formed by a braided or stranded construct, and the like. In some embodiments, one or more of the elongate members forming the anchor assembly 200 may be essentially flat (i.e., such that the width to thickness ratio is about 2:1, about 3:1, about 4:1, about 5:1, or greater than about 5:1). In some examples, one or more of the elongate members forming the anchor assembly 200 may be formed using a center-less grind technique, such that the diameter of the elongate members varies along the length of the elongate members.
The anchor assembly 200 may include features that are directed to enhancing one or more desirable functional performance characteristics of the prosthetic mitral valve devices. For example, some features of the anchor assembly 200 may be directed to enhancing the conformability of the prosthetic mitral valve devices. Such features may facilitate improved performance of the prosthetic mitral valve devices by allowing the devices to conform to irregular tissue topographies and/or dynamically variable tissue topographies, for example. Such conformability characteristics can be advantageous for providing effective and durable performance of the prosthetic mitral valve devices. In some embodiments of the anchor assembly 200, some portions of the anchor assembly 200 are designed to be more conformable than other portions of the same anchor assembly 200. That is, the conformability of a single anchor assembly 200 can be designed to be different at various areas of the anchor assembly 200.
In some embodiments, the anchor assembly 200 includes features for enhanced in vivo radiographic visibility. In some embodiments, portions of the anchor assembly 200, such as one or more of the anchor feet 220a, 220b, 220c, and 220d, may have one or more radiopaque markers attached thereto. In some embodiments, some or all portions of the anchor assembly 200 are coated (e.g., sputter coated) with a radiopaque coating.
Still referring to
In some embodiments, the anchor feet 220a, 220b, 220c, and 220d have a height ranging from about 8 mm to about 12 mm, or more than about 12 mm. In some embodiments, the anchor feet 220a, 220b, 220c, and 220d have a gutter engaging surface area (when fabric covered) ranging from about 6 mm2 to about 24 mm2. In some embodiments, the anchor feet 220a, 220b, 220c, and 220d each have essentially the same gutter engaging surface area. In particular embodiments, one or more of the anchor feet 220a, 220b, 220c, and 220d has a different gutter engaging surface area than one or more of the other anchor feet 220a, 220b, 220c, and 220d. The anchor feet 220a, 220b, 220c, and 220d can have widths ranging within about 1.5 mm to about 4.0 mm or more, and lengths ranging within about 3 mm to about 6 mm or more. The anchor feet 220a, 220b, 220c, and 220d are sized and shaped so that the anchor assembly 200 does not significantly impair the natural function of mitral valve chordae tendineae, the native mitral valve leaflets, and papillary muscles even after the anchor assembly is anchored at the mitral valve site.
As described previously, the anchor assembly 200 is designed to avoid interference with the functioning of the native mitral valve 17. Therefore, the anchor assembly 200 can be implanted within the native mitral valve 17 some time prior to the deployment therein of a replacement valve assembly, without degradation of valve 17 function during the period of time between the anchor implantation and the valve implantation (whether that time is on the order of minutes, or even several days or months). To avoid such interference between the anchor assembly 200 and the native mitral valve 17, the inter-annular connections 270a, 270b, 270c, and 270d pass through the coaptation line 32 approximately. More particularly, the left anterior inter-annular connection 270a passes through the coaptation line 32 adjacent to the anterolateral commissure 30a. In like manner, the right anterior inter-annular connection 270d passes through the coaptation line 32 adjacent to the posteromedial commissure 30b. In some implementations, the left posterior inter-annular connection 270b and right posterior inter-annular connection 270c pass through the native mitral valve 17 in locations that are posteriorly biased from the natural coaptation line 32. The posterior leaflet 22 will tend to compliantly wrap around the left posterior inter-annular connection 270b and right posterior inter-annular connection 270c to facilitate sealing of the mitral valve 17, with the anchor assembly 200 coupled thereto.
In reference to
In the depicted embodiment, the covering material 270 is disposed essentially on the entire anchor assembly 200. In some embodiments, the covering material 270 is disposed on one or more portions of the anchor assembly 200, while one or more other portions of the anchor assembly 200 do not have the covering material 270 disposed thereon. While the depicted embodiment includes the covering material 270, the covering material 270 is not required in all embodiments. In some embodiments, two or more portions of covering material 270, which can be separated and/or distinct from each other, can be disposed on the anchor assembly 200. That is, in some embodiments a particular type of covering material 270 is disposed on some areas of the anchor assembly 200 and a different type of covering material 270 is disposed on other areas of the anchor assembly 200.
In some embodiments, the covering material 270, or portions thereof, comprises a fluoropolymer, such as an expanded polytetrafluoroethylene (ePTFE) polymer. In some embodiments, the covering material 270, or portions thereof, comprises a polyester, a silicone, a urethane, ELAST-EON™ (a silicone and urethane polymer), another biocompatible polymer, DACRON®, polyethylene terephthalate (PET), copolymers, or combinations and subcombinations thereof. In some embodiments, the covering material 270 is manufactured using techniques such as, but not limited to, extrusion, expansion, heat-treating, sintering, knitting, braiding, weaving, chemically treating, and the like. In some embodiments, the covering material 270, or portions thereof, comprises a biological tissue. For example, in some embodiments the covering material 270 can include natural tissues such as, but not limited to, bovine, porcine, ovine, or equine pericardium. In some such embodiments, the tissues are chemically treated using glutaraldehyde, formaldehyde, or triglycidylamine (TGA) solutions, or other suitable tissue crosslinking agents.
In the depicted embodiment, the covering material 270 is disposed on the interior and the exterior of the anchor assembly 200. In some embodiments, the covering material 270 is disposed on the just the exterior of the anchor assembly 200. In some embodiments, the covering material 270 is disposed on the just the interior of the anchor assembly 200. In some embodiments, some portions of the anchor assembly 200 are covered by the covering material 270 in a different manner than other portions of the anchor assembly 200.
In some embodiments, the covering material 270 is attached to at least some portions of the anchor assembly 200 using an adhesive. In some embodiments, FEP (fluorinated ethylene propylene) is used as an adhesive to attach the covering material 270 to the anchor assembly 200, or portions thereof. For example, an FEP coating can be applied to some or all portions of the anchor assembly 200, and the FEP can act as a bonding agent to adhere the covering material 270 to the anchor assembly 200. In some embodiments, wrapping, stitching, lashing, banding, and/or clips, and the like can be used to attach the covering material 270 to the anchor assembly 200. In some embodiments, a combination of techniques are used to attach the covering material 270 to the anchor assembly 200.
In some embodiments, the covering material 270, or portions thereof, has a microporous structure that provides a tissue ingrowth scaffold for durable sealing and/or supplemental anchoring strength of the anchor assembly 200. In some embodiments, the covering material 270 is made of a membranous material that inhibits or reduces the passage of blood through the covering material 270. In some embodiments, the covering material 270, or portions thereof, has a material composition and/or configuration that inhibits or prevents tissue ingrowth and/or endothelialization to the covering material 270.
In some embodiments, the covering material 270 can be modified by one or more chemical or physical processes that enhance certain physical properties of the covering material 270. For example, a hydrophilic coating may be applied to the covering material 270 to improve the wettability and echo translucency of the covering material 270. In some embodiments, the covering material 270 may be modified with chemical moieties that promote or inhibit one or more of endothelial cell attachment, endothelial cell migration, endothelial cell proliferation, and resistance to thrombosis. In some embodiments, the covering material 270 may be modified with covalently attached heparin or impregnated with one or more drug substances that are released in situ.
In some embodiments, covering material 270 is pre-perforated to modulate fluid flow through the covering material 270 and/or to affect the propensity for tissue ingrowth to the covering material 270. In some embodiments, the covering material 270 is treated to make the covering material 270 stiffer or to add surface texture. For example, in some embodiments the covering material 270 is treated with FEP powder to provide a stiffened covering material 270 or roughened surface on the covering material 270. In some embodiments, selected portions of the covering material 270 are so treated, while other portions of the covering material 270 are not so treated. Other covering material 270 material treatment techniques can also be employed to provide beneficial mechanical properties and tissue response interactions. In some embodiments, portions of the covering material 270 have one or more radiopaque markers attached thereto to enhance in vivo radiographic visualization.
Referring now to
These figures illustrate the supra-annular structures and sub-annular structures of the anchor assembly 200 in their relationships with the native mitral valve 17. For example, the closed state of the native mitral valve 17 in
In contrast, in
Referring to
In some implementations, with the primary deflectable catheter 120 positioned with its distal end in the left atrium 16, the valve delivery sheath 170 is installed into a lumen of the primary deflectable catheter 120 (over the distal pusher catheter 160) and advanced through the primary deflectable catheter 120. As described further below, in some embodiments the valve delivery sheath 170 is preloaded with a prosthetic valve assembly and other components of the delivery system 100. The primary deflectable catheter 120 may be the same catheter that was used to deliver the anchor assembly 200, or it may be a different catheter (but still referred to here as the primary deflectable catheter 120 for simplicity sake).
In some embodiments, the valve delivery sheath 170 can be made from the materials described above in reference to the primary deflectable catheter 120. In some embodiments, the valve delivery sheath 170 has an outer diameter in the range of about 20 Fr to about 28 Fr (about 6.7 mm to about 9.3 mm). In some embodiments, the valve delivery sheath 170 has an outer diameter in the range of about 14 Fr to about 24 Fr (about 4.7 mm to about 8.0 mm).
In the depicted embodiment, the valve delivery sheath 170 includes a flared distal end portion 172. In some embodiments, no such flared distal end portion 172 is included. The flared distal end portion 172 can collapse to a lower profile when constrained within the primary deflectable catheter 120. When the flared distal end portion 172 is expressed from the primary deflectable catheter 120, the flared distal end portion 172 can self-expand to the flared shape. In some embodiments, the material of the flared distal end portion 172 includes pleats or folds, may be a continuous flared end or may be separated into sections such as flower pedals, and may include one or more resilient elements that bias the flared distal end portion 172 to assume the flared configuration in the absence of restraining forces (such as from containment within the primary deflectable catheter 120). The flared distal end portion 172 can be advantageous, for example, for recapturing the valve assembly within the lumen of the valve delivery sheath 170 after the valve assembly has been expressed from the flared distal end portion 172.
In some embodiments, the maximum outer diameter of the flared distal end portion 172 is in a range of about 30 Fr to about 34 Fr (about 10.0 mm to about 11.3 mm). In some embodiments, the maximum outer diameter of the flared distal end portion 172 is in a range of about 32 Fr to about 44 Fr (about 10.7 mm to about 14.7 mm). In some embodiments, the maximum outer diameter of the flared distal end portion 172 is in a range of about 24 Fr to about 30 Fr (about 8.0 mm to about 10.0 mm). In some embodiments, the maximum outer diameter of the flared distal end portion 172 is less than about 24 Fr (about 8.0 mm) or greater than about 44 Fr (about 14.7 mm).
Referring to
The valve assembly 300 can be releasably coupled to the valve delivery catheter 180 and retained in a low-profile configuration. In some embodiments, both the distal and proximal ends of the valve assembly 300 are releasably coupled to the valve delivery catheter 180. In some embodiments, just one of the distal end or the proximal end of the valve assembly 300 is releasably coupled to the valve delivery catheter 180. In particular embodiments, one or more control wires may be included to releasably couple one or more portions of the valve assembly 300 to the valve delivery catheter 180.
Referring to
Referring again to
Referring to
In some implementations, the aforementioned rotation of the valve assembly 300 can be performed as follows. As shown in
Referring now also to
Coaxial alignment between the valve assembly 300 and the anchor assembly 200, as described above, is achieved by virtue of the valve delivery catheter 180 being slidably disposed over the distal pusher catheter 160. Linear alignment between the valve assembly 300 and the anchor assembly 200 can be achieved by the interaction of a distal end feature 182 of the valve delivery catheter 180 and the hub 210 of the anchor assembly 200. For example, in some embodiments an abutting of the distal end feature 182 and the hub 210 can result in proper linear alignment between the valve assembly 300 and the anchor assembly 200.
Relative rotational alignment between the valve assembly 300 and the anchor assembly 200 (about their axes) can be achieved in various manners. For example, in some embodiments the valve delivery catheter 180 is mechanically keyed to the distal pusher catheter 160 to slidably fix a desired rotational alignment between the valve assembly 300 and the anchor assembly 200. In some embodiments, other types of mechanical features (e.g., pins/holes, protrusions/receptacles, etc.) can be included to facilitate a desired rotational/spin alignment between the valve assembly 300 and the anchor assembly 200. Alternatively, or additionally, radiopaque markers can be included on the valve assembly 300 and on the anchor assembly 200 in locations and/or patterns that are indicative of the relative rotational orientation (about their axes) of the valve assembly 300 and the anchor assembly 200. In some embodiments, (e.g., when the valve delivery catheter 180 “torqueable”) the valve delivery catheter 180 can be rotated about its axis until the markers are in proper position relative to the anchor assembly 200, prior to final expansion of valve assembly 300. Fluoroscopy can be used to attain a desired relative orientation of the radiopaque markers, and of the valve assembly 300 and the anchor assembly 200 correspondingly.
Referring to
The valve assembly 300 includes a proximal end portion 302 and a distal end portion 304. The valve assembly includes a flared external skirt portion 303 and defines an interior orifice portion 305. When the valve assembly 300 is implanted in a native mitral valve, the proximal end portion 302 is located supra-annular (in the left atrium) and the distal end portion 304 is located sub-annular (in the left ventricle). The proximal end portion 302 defines the generally circular entrance orifice of the valve assembly 300, as described further below.
In the depicted embodiment, the valve assembly 300 generally flares outward along a distal direction. Said differently, the distal end portion 304 is flared outward in comparison to the proximal end portion 302. Accordingly, the proximal end portion 302 defines a smaller outer profile in comparison to the distal end portion 304. However, some regions of the distal end portion 304 bow inwardly. In particular, for example, a posteromedial commissural corner 330a and anterolateral commissural corner 330b of the valve assembly 300 may bow inwardly. It should be understood that the outward flare of the distal end portion 304 in comparison to the proximal end portion 302 is merely one example configuration for a profile of the valve assembly 300. In some embodiments, for example, a shoulder (a portion of the valve assembly 300 having the largest outer periphery) is located proximal of the middle of the valve assembly 300.
The valve assembly 300 also includes an anterior side 306 between the posteromedial commissural corner 330a and anterolateral commissural corner 330b. When the valve assembly 300 is implanted in a native mitral valve, the anterior side 306 faces the anterior leaflet of the native mitral valve. The anterior side 306 of the distal end portion 304 defines a generally flat surface, whereas the other sides of the distal end portion 304 are rounded. Hence, the periphery of the distal end portion 304 is generally D-shaped. The D-shaped periphery of the distal end portion 304 provides the valve assembly 300 with an advantageous outer profile for interfacing and sealing with the native mitral valve. As described further below, sealing is attained by coaptation between the D-shaped periphery of the distal end portion 304 and the leaflets of the native mitral valve, and, in some embodiments, between the D-shaped periphery in the region of the skirt 303 with the native valve annulus.
In the depicted embodiment, the proximal end portion 302 of the valve assembly 300 includes three atrial leaflet arches 310a, 310b, and 310c that together define an undulating ring at the proximal end portion 302. Each of the leaflet arches 310a, 310b, and 310c includes an apex having an attachment hole 312a, 312b, and 312c respectively. In some embodiments, the attachment holes 312a, 312b, and 312c are used for coupling the proximal end of the valve assembly 300 to a delivery catheter (e.g., valve delivery catheter 180 of
The valve assembly 300 also includes three commissural posts 320a, 320b, and 320c that each extend distally from the intersections of the three leaflet arches 310a, 310b, and 310c. The commissural posts 320a, 320b, and 320c are disposed at about 120° apart from each other. The commissural posts 320a, 320b, and 320c each have a series of holes that can be used for attachment of leaflets, such as by suturing. The three leaflet arches 310a, 310b, and 310c and the three commissural posts 320a, 320b, and 320c are areas on the valve assembly 300 to which three prosthetic valve leaflets become attached to comprise a tri-leaflet occluder (e.g., refer to
As best seen in
Referring to
The valve assembly 300 includes a covering 340. The covering 340 can be made of any of the materials and constructed using any of the techniques described above in reference to covering 270. Additionally, in some embodiments the covering 340 can comprise natural tissues such as, but not limited to, bovine, porcine, ovine, or equine pericardium. In some such embodiments, the tissues are chemically cross-linked using glutaraldehyde, formaldehyde, or triglycidyl amine solution, or other suitable crosslinking agents.
When the valve assembly 300 and the anchor assembly 200 are coupled together, the valve assembly 300 is geometrically interlocked within the interior of the anchor assembly 200 (e.g., in some embodiments by virtue of the tapered shape of the valve assembly 300 within the supra-annular ring and interior space of the anchor assembly 200). In particular, in some embodiments the valve assembly 300 is contained within the interior space between the supra-annular ring 250 and the sub-annular support arms 230a, 230b, 230c, and 230d. As described above, the interlocked arrangement between the valve assembly 300 and the anchor assembly 200 is accomplished by positioning a valve assembly 300 in a low-profile configuration within the interior of the anchor assembly 200 and then allowing expansion of the valve assembly 300 within the interior of the anchor assembly 200 (e.g., refer to
Referring to
In some embodiments, such as the depicted embodiment, valve assembly 300 includes three leaflets 350a, 350b, and 350c that perform the occluding function of the prosthetic mitral valve 400. The cusps of the three leaflets 350a, 350b, and 350c are fixed to the three atrial leaflet arches 310a, 310b, and 310c, and to the three commissural posts 320a, 320b, and 320c (refer to
The three leaflets 350a, 350b, and 350c can be comprised of natural or synthetic materials. For example, the three leaflets 350a, 350b, and 350c can be comprised of any of the materials described above in reference to the covering 340, including the natural tissues such as, but not limited to, bovine, porcine, ovine, or equine pericardium. In some such embodiments, the tissues are chemically cross-linked using glutaraldehyde, formaldehyde, or triglycidyl amine solution, or other suitable crosslinking agents. In some embodiments, the leaflets 350a, 350b, and 350c have a thickness in a range of about 0.005″ to about 0.020″ (about 0.13 mm to about 0.51 mm), or about 0.008″ to about 0.012″ (about 0.20 mm to about 0.31 mm). In some embodiments, the leaflets 350a, 350b, and 350c have a thickness that is less than about 0.005″ (about 0.13 mm) or greater than about 0.020″ (about 0.51 mm).
In some embodiments, the occluding function of the prosthetic mitral valve 400 can be performed using configurations other than a tri-leaflet occluder. For example, bi-leaflet, quad-leaflet, or mechanical valve constructs can be used in some embodiments.
Referring to
One feature that enhances the sealing of the prosthetic mitral valves provided herein pertains to the shape of the prosthetic valve framework in relation to the shape of the native mitral valve. As described above, the annulus of a native mitral valve is generally D-shaped (e.g., refer to
Another feature that enhances the sealing of the prosthetic mitral valves provided herein pertains to the size of the selected prosthetic valve in relation to the size of the native mitral valve, especially during systole. In some implementations, a selected prosthetic valve will intentionally have an outer profile (when unconstrained) that is equal to or slightly larger than the size of the annulus of the native mitral valve. That is, in the area on the valve surface that is intended to be adjacent to the native valve annulus, the size of the valve may result in a line-to-line fit or a slight interference fit with the native valve annulus. Hence, in some implementations the atrium-to-ventricle sealing during diastole is provided by the line-to-line fit or slight interference fit between the valve and the native valve annulus.
Another feature that enhances the sealing of the prosthetic mitral valves provided herein pertains to the relative geometric orientation of sealing surfaces on the prosthetic valve in relation to the annulus of the native mitral valve. While in some implementations, some sealing is provided by the mechanical fit between the outer profile of the valve and the receiving structure of the native mitral valve, in some implementations substantial sealing is provided by coaptation between the native leaflets and sealing surfaces on the perimeter of the prosthetic valve (to thereby create a contact seal during diastole and a left ventricle pressurized seal during systole). This type of sealing may be referred to herein as a leaflet to valve body seal. As described further below, the prosthetic mitral valves provided herein have sealing surfaces that are geometrically oriented in relation to the native valve annulus so that a leaflet to valve body seal is provided. While the leaflet to valve body seal is not entirely a mechanically compressive type of seal or an attachment onto the native tissue (active fixation) type of seal, in some embodiments such mechanical or attachment type of seals may alternatively or additionally be incorporated.
In some implementations, an effective leaflet to valve body seal (not based entirely on compression or attachment) may necessitate some native leaflet movement to the sealing surface of the valve body. Hence, a valve body shape that mimics the shape of the native mitral valve is advantageous. As described above, in some embodiments the outer periphery of the valve assemblies provided herein have a D-shaped periphery that generally correlates with the D-shaped annulus of native mitral valves. Accordingly, the movement distance of the native valve leaflets to the sealing surface of the valve body can be minimized (or essentially eliminated in some implementations), and sealing can thereby be enhanced.
In addition, an effective leaflet to valve body seal exhibits contiguous coaptation between the native leaflets and prosthetic valve body around the entire periphery of the prosthetic valve body. As described further below, the profiles of the prosthetic mitral valves provided herein are designed to interface with the native leaflets so as to provide contiguous coaptation around the entire periphery of the prosthetic valve. To accomplish this, in some embodiments the profile of some regions of the prosthetic mitral valves are different than the profile of other regions of the same valve (e.g., in correspondence with differing anatomical features in various portions of the native mitral valve).
Referring to
In regard to sealing between a prosthetic mitral valve and a native mitral valve, the differing anatomical features of various portions of the native mitral valve 17 make it advantageous to consider the mitral valve 17 as having three distinct sealing regions that together comprise the entirety of the mitral valve 17. The three distinct sealing regions are: an anterior region 25a, a posterior region 25b, and two commissural regions 25c. The anterior region 25a extends generally linearly between the left and right trigones 134a and 134b. The posterior region 25b comprises the middle scallop 24b and posterior portions of the lateral scallop 24a and medial scallop 24c. The commissural regions 25c extend between the anterior region 25a and the posterior region 25b. The commissural regions 25c generally encompass the commissures 30a and 30b, and anterior portions of the lateral scallop 24a and medial scallop 24c. These three sealing regions 25a, 25b, and 25c will be referenced again in regard to
Referring to
The geometric variable S quantifies the radial distance from the annulus 28 to the adjacent prosthetic valve framework surface. A negative S-value indicates that the annulus 28 and the adjacent prosthetic valve surface are spaced apart from each other. For example, an S-value of negative 2 mm indicates that there is a 2 mm space between the annulus 28 and the adjacent prosthetic valve surface. When S equals zero, it indicates that the annulus 28 and the adjacent prosthetic valve surface are in contact with each other in a line-to-line fit relationship. When S is a positive number, it indicates that the annulus 28 and the adjacent prosthetic valve surface are in an interference fit relationship. In other words, when S is a positive number some compressive force is being applied to the annulus 28 by the adjacent prosthetic valve surface.
The geometric variable H quantifies the distance from the superior limit (upper edge) to the inferior limit (lower edge) of the sealing surface on the prosthetic valve. H-values are measured downward (in reference to the illustration). For example, an H-value of 10 mm indicates that, for a particular sealing region, the sealing surface on the prosthetic valve ends 10 mm below the superior limit of the sealing surface. In another example, when the superior limit is at the annulus 28, an H-value of 7 mm indicates that the inferior limit of the sealing surface is 7 mm below the annulus 28. In general, the superior limit of the sealing surface on the prosthetic valve is either at, slightly above, or slightly below the annulus 28 (e.g., about 2 mm above or about 2 mm below the annulus 28 in some embodiments).
The geometric variable W quantifies the radial distance from the superior limit of the sealing surface to the inferior limit of the sealing surface on the prosthetic valve. A negative W-value indicates that the inferior limit of the sealing surface is positioned radially inward in comparison to the superior limit of the sealing surface (e.g., at least a portion of the sealing surface is flared or bowed inward at the distal end). A positive W-value indicates that the inferior limit of the sealing surface is positioned radially outward in comparison to superior limit of the sealing surface (e.g., at least a portion of the sealing surface is flared or bowed outward at the distal end). A W-value of zero indicates that the inferior limit of the sealing surface is positioned at the same radial position as the superior limit of the sealing surface.
Referring to
Referring to
Referring to
Referring to
In some embodiments the H-value of the anterior sealing surface of the prosthetic mitral valve is about 14 millimeters. In other words, in some embodiments the distance from the superior edge of the anterior sealing surface to the inferior edge of the anterior sealing surface is about 14 millimeters. More specifically, the H-value of the anterior sealing surface can be divided into two portions: (1) a superior portion, HLVOT and (2) an inferior portion, HTISSUE. The HLVOT-value generally corresponds to the distance from the superior edge of the anterior sealing surface to the inferior end of the valve frame 301 at various places along the anterior sealing surface 360a (refer to
While in the depicted embodiment the total H-value is about 14 millimeters, in some embodiments the H-value is in a range of about 8 millimeters to about 10 millimeters, or about 10 millimeters to about 12 millimeters, or about 12 millimeters to about 14 millimeters, or about 14 millimeters to about 16 millimeters, or about 13 millimeters to about 15 millimeters. In some embodiments, the H-value can be less than about 8 millimeters or more than about 16 millimeters.
In some embodiments the W-value of the anterior sealing surface of the prosthetic mitral valve is about negative 2 millimeters. In other words, in some embodiments the radial distance from the superior edge of the anterior sealing surface to the inferior edge of the anterior sealing surface on the prosthetic valve is about negative 2 millimeters. A W-value of negative 2 millimeters indicates that the lower edge of the anterior sealing surface is positioned radially inward in comparison to the superior edge of the anterior sealing surface by about 2 millimeters. This also indicates that the sub-annular anterior valve assembly is flared or bowed inward, such as indicated by valve body profile line 362a. While in the depicted embodiment the W-value is about negative 2 millimeters, in some embodiments the W-value is in a range of about negative 6 millimeters to about negative 4 millimeters, or about negative 4 millimeters to about negative 2 millimeters, or about negative 2 millimeters to about zero millimeters, or about zero millimeters to about positive 2 millimeters, or about negative 3 millimeters to about negative 1 millimeter. In some embodiments, the W-value can be more negative than about negative 6 millimeters or more positive than about positive 2 millimeters.
Referring to
In some embodiments, the H-value of the commissural sealing surface of the prosthetic mitral valve is in a range of about 8 millimeters to about 14 millimeters. In other words, in some embodiments the distance from the native valve annulus to the lower (inferior) edge of the commissural sealing surface is in a range of about 8 millimeters to about 14 millimeters. This range, from about 8 millimeters to about 14 millimeters, is at least partly a result of the shape of a commissural corner 364 (refer to
In some embodiments the W-value of the commissural sealing surface of the prosthetic mitral valve is about negative 2 millimeters. In other words, in some embodiments the radial distance from the superior (upper) edge of the commissural sealing surface to the inferior (lower) edge of the commissural sealing surface on the prosthetic valve is about negative 2 millimeters. A W-value of negative 2 millimeters indicates that the lower edge of the commissural sealing surface is positioned radially inward in comparison to the upper edge of the commissural sealing surface by about 2 millimeters. This also indicates that the sub-annular commissural valve assembly is flared or bowed inward, such as indicated by valve body profile line 362b. While in the depicted embodiment the W-value is about negative 2 millimeters, in some embodiments the W-value is in a range of about negative 6 millimeters to about negative 4 millimeters, or about negative 4 millimeters to about negative 2 millimeters, or about negative 2 millimeters to about zero millimeters, or about zero millimeters to about positive 2 millimeters, or about negative 3 millimeters to about negative 1 millimeter. In some embodiments, the W-value can be more negative than about negative 6 millimeters or more positive than about positive 2 millimeters.
Referring to
In some embodiments, the H-value of the posterior sealing surface of the prosthetic mitral valve is about 8 millimeters. In other words, in some embodiments the distance from the native valve annulus to the lower (inferior) edge of the posterior sealing surface is about 8 millimeters. While in the depicted embodiment the H-value is about 8 millimeters, in some embodiments the H-value is in a range of about 4 millimeters to about 6 millimeters, or about 6 millimeters to about 8 millimeters, or about 8 millimeters to about 10 millimeters, or about 10 millimeters to about 12 millimeters, or about 7 millimeters to about 9 millimeters. In some embodiments, the H-value can be less than about 4 millimeters or more than about 12 millimeters.
In some embodiments, the W-value of the posterior sealing surface of the prosthetic mitral valve is about positive 2 millimeters. In other words, in some embodiments the radial distance from the upper (superior) edge of the posterior sealing surface to the lower (inferior) edge of the posterior sealing surface on the prosthetic valve is about positive 2 millimeters. A W-value of positive 2 millimeters indicates that the lower edge of the posterior sealing surface is positioned radially outward in comparison to the upper edge of the posterior sealing surface by about 2 millimeters. This also indicates that the sub-annular posterior valve assembly is flared or bowed outward, such as indicated by valve body profile line 362c. While in the depicted embodiment the W-value is about positive 2 millimeters, in some embodiments the W-value is in a range of about negative 4 millimeters to about negative 2 millimeters, or about negative 2 millimeters to about zero millimeters, or about zero millimeters to about positive 2 millimeters, or about positive 2 millimeters to about positive 4 millimeters, or about positive 1 millimeter to about positive 3 millimeters. In some embodiments, the W-value can be more negative than about negative 2 millimeters or more positive than about positive 3 millimeters.
Referring to
Referring to
The first fluoroscopic image 700 illustrates an area of reduced blood flow 710 caused by an LVOT obstruction from a prosthetic mitral valve 720. The second fluoroscopic image 730 illustrates improved blood flow 740 through the LVOT. The improved blood flow 740 can be a result of less obstruction attributable to the prosthetic mitral valve 750. For example, in some embodiments the prosthetic mitral valve 750 can be positioned or designed so that less structure of the valve 750 is below the native mitral valve annulus, resulting in less structure of the valve 750 within the LVOT. Additionally, the prosthetic mitral valve 750 can be positioned or designed so that less structure of the valve 750 is within the LVOT such as by tapering, bowing, or shaping the structure away from the LVOT.
Referring again to
Referring also to
Using geometry, the LVOT obstruction 514 distance (identified as “O” in the equation below) can be calculated using the following equation:
where:
The following examples are provided to illustrate Equation #1 above.
By comparing Examples #1 and #5, with Examples #2, #3, and #4 it can be ascertained that O (the LVOT obstruction) tends to be less when θ is greater. By comparing Example #3 and Example #4, it is seen that a greater HLVOT tends to result in a higher O. By comparing Example #2 and Example #3, it can be determined that the effect of a greater S-value can be offset by a more negative W-value. In summary, one of ordinary skill in the art can use these teachings to select an R-value, S-value, HLVOT-value, and W-value for a given θ (based on patient anatomy) in effort to attain an acceptable O (the LVOT obstruction).
Referring to
In some implementations, the positioning of the hub 210 relative to the anatomical features of the mitral valve 17 is relevant to facilitating substantially unhindered leaflets 20 and 22 and chordae tendineae 40. For example, a depth 810 of the hub 210 in the left ventricle 18 is one relevant consideration. In order to substantially prevent hindrances to the leaflets 20 and 22 and chordae tendineae 40, the depth 810 should be at least slightly below the coaptation depth of the mitral valve 17. The coaptation depth is the greatest vertical distance from the annulus of the mitral valve 17 to an area of coaptation between the native leaflets 20 and 22. Hence, positioning the hub 210 below the coaptation depth will facilitate substantially unhindered leaflets 20 and 22 and chordae tendineae 40. In some implementations, the depth 810 is in a range of about 14 mm to about 20 mm, or about 10 mm to about 16 mm, or about 12 mm to about 18 mm, or about 16 mm to about 22 mm. In some implementations, the depth 810 is less than about 10 mm or greater than about 22 mm.
The positioning of the hub 210 relative to the line of coaptation between the leaflets 20 and 22 (e.g., the line of coaptation 32 shown in
In some implementations, the angular positioning of the left anterior sub-annular support arm 230a, the left posterior sub-annular support arm 230b, the right posterior sub-annular support arm 230c, and the right anterior sub-annular support arm 230d in relation to the native mitral valve 17 is relevant to facilitating substantially unhindered leaflets 20 and 22 and chordae tendineae 40. In some implementations, the sub-annular support arms 230a, 230b, 230c, and 230d are arranged symmetrically in relation to a left ventricular long axis (LAX) 840. That is, the LAX 840 bisects an anterior support arm angle 830 and a posterior support arm angle 820.
To minimize disturbances to the anterior leaflet 20 and chordae tendineae 40, the anterior support arms 220a and 220d are positioned essentially between the chordae tendineae 40. In some embodiments, the anterior support arm angle 830 is in a range of about 100° to about 135°, or about 80° to about 120°, or about 120° to about 160°. To minimize disturbances to the posterior leaflet 22 and chordae tendineae 40, in some implementations the posterior support arms 220b and 220b may extend essentially amongst the chordae tendineae 40. In some embodiments, the posterior support arm angle 820 is in a range of about 50° to about 120°, or about 40° to about 80°, or about 60° to about 100°, or about 80° to about 120°, or about 100° to about 140°.
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
This application is a continuation of U.S. patent application Ser. No. 15/685,596, filed on Aug. 24, 2017, which is a continuation of U.S. patent application Ser. No. 14/674,349 filed on Mar. 31, 2015, which is a continuation of U.S. patent application Ser. No. 14/673,055 filed Mar. 30, 2015, which is a continuation of U.S. patent application Ser. No. 14/671,577 filed Mar. 27, 2015, which claims the benefit of U.S. Application Ser. No. 62/067,907, filed Oct. 23, 2014. The disclosures of the prior applications are considered part of and are incorporated by reference in the disclosure of this application.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4680031 | Alonso | Jul 1987 | A |
| 5423887 | Love et al. | Jun 1995 | A |
| 5662704 | Gross | Sep 1997 | A |
| 5855601 | Bessler et al. | Jan 1999 | A |
| 5984959 | Robertson et al. | Nov 1999 | A |
| 6086612 | Jansen | Jul 2000 | A |
| 6113631 | Jansen | Sep 2000 | A |
| 6296662 | Caffey | Oct 2001 | B1 |
| 6309417 | Spence et al. | Oct 2001 | B1 |
| 6332893 | Mortier et al. | Dec 2001 | B1 |
| 6358277 | Duran | Mar 2002 | B1 |
| 6425916 | Garrison et al. | Jul 2002 | B1 |
| 6530952 | Vesely | Mar 2003 | B2 |
| 6569196 | Vesely | May 2003 | B1 |
| 6582462 | Andersen et al. | Jun 2003 | B1 |
| 6629534 | St et al. | Oct 2003 | B1 |
| 6652578 | Bailey et al. | Nov 2003 | B2 |
| 6730118 | Spenser et al. | May 2004 | B2 |
| 6730121 | Ortiz et al. | May 2004 | B2 |
| 6767362 | Schreck | Jul 2004 | B2 |
| 6769434 | Liddicoat et al. | Aug 2004 | B2 |
| 6790229 | Berreklouw | Sep 2004 | B1 |
| 6830584 | Seguin | Dec 2004 | B1 |
| 6883522 | Spence et al. | Apr 2005 | B2 |
| 6893459 | Macoviak | May 2005 | B1 |
| 6893460 | Spenser et al. | May 2005 | B2 |
| 6908481 | Cribier | Jun 2005 | B2 |
| 6949122 | Adams et al. | Sep 2005 | B2 |
| 7011681 | Vesely | Mar 2006 | B2 |
| 7018406 | Seguin et al. | Mar 2006 | B2 |
| 7044966 | Svanidze et al. | May 2006 | B2 |
| 7101396 | Artof et al. | Sep 2006 | B2 |
| 7147663 | Berg et al. | Dec 2006 | B1 |
| 7160322 | Gabbay | Jan 2007 | B2 |
| 7175656 | Khairkhahan | Feb 2007 | B2 |
| 7217287 | Wilson et al. | May 2007 | B2 |
| 7252682 | Seguin | Aug 2007 | B2 |
| 7320704 | Lashinski et al. | Jan 2008 | B2 |
| 7329278 | Seguin et al. | Feb 2008 | B2 |
| 7381218 | Schreck | Jun 2008 | B2 |
| 7381220 | Macoviak et al. | Jun 2008 | B2 |
| 7393360 | Spenser et al. | Jul 2008 | B2 |
| 7442204 | Schwammenthal et al. | Oct 2008 | B2 |
| 7503930 | Sharkawy et al. | Mar 2009 | B2 |
| 7510575 | Spenser et al. | Mar 2009 | B2 |
| 7524330 | Berreklouw | Apr 2009 | B2 |
| 7524331 | Birdsall | Apr 2009 | B2 |
| 7578843 | Shu | Aug 2009 | B2 |
| 7585321 | Cribier | Sep 2009 | B2 |
| 7597711 | Drews et al. | Oct 2009 | B2 |
| 7618446 | Andersen et al. | Nov 2009 | B2 |
| 7625403 | Krivoruchko | Dec 2009 | B2 |
| 7632308 | Loulmet | Dec 2009 | B2 |
| 7708775 | Rowe et al. | May 2010 | B2 |
| 7717955 | Lane et al. | May 2010 | B2 |
| 7722666 | Lafontaine | May 2010 | B2 |
| 7727276 | Machiraju | Jun 2010 | B2 |
| 7748389 | Salahieh et al. | Jul 2010 | B2 |
| 7776083 | Vesely | Aug 2010 | B2 |
| 7780725 | Haug et al. | Aug 2010 | B2 |
| 7785364 | Styrc | Aug 2010 | B2 |
| 7837727 | Goetz et al. | Nov 2010 | B2 |
| 7896915 | Guyenot et al. | Mar 2011 | B2 |
| 7914569 | Nguyen et al. | Mar 2011 | B2 |
| 7935144 | Robin et al. | May 2011 | B2 |
| 7947072 | Yang et al. | May 2011 | B2 |
| 7947075 | Goetz et al. | May 2011 | B2 |
| 7959672 | Salahieh et al. | Jun 2011 | B2 |
| 7981153 | Fogarty et al. | Jul 2011 | B2 |
| 7988725 | Gross et al. | Aug 2011 | B2 |
| 8016882 | Macoviak et al. | Sep 2011 | B2 |
| 8025695 | Fogarty et al. | Sep 2011 | B2 |
| 8048153 | Salahieh et al. | Nov 2011 | B2 |
| 8052749 | Salahieh et al. | Nov 2011 | B2 |
| 8055360 | Park et al. | Nov 2011 | B2 |
| 8057540 | Letac et al. | Nov 2011 | B2 |
| 8062355 | Figulla et al. | Nov 2011 | B2 |
| 8092518 | Schreck | Jan 2012 | B2 |
| 8092521 | Figulla et al. | Jan 2012 | B2 |
| 8092524 | Nugent et al. | Jan 2012 | B2 |
| 8123801 | Milo | Feb 2012 | B2 |
| 8133270 | Kheradvar et al. | Mar 2012 | B2 |
| 8142492 | Forster et al. | Mar 2012 | B2 |
| 8157852 | Bloom et al. | Apr 2012 | B2 |
| 8157853 | Laske et al. | Apr 2012 | B2 |
| 8163011 | Rankin | Apr 2012 | B2 |
| 8172898 | Alferness et al. | May 2012 | B2 |
| 8182528 | Salahieh et al. | May 2012 | B2 |
| 8182530 | Huber | May 2012 | B2 |
| 8206437 | Bonhoeffer et al. | Jun 2012 | B2 |
| 8231670 | Salahieh et al. | Jul 2012 | B2 |
| 8236049 | Rowe et al. | Aug 2012 | B2 |
| 8246677 | Ryan | Aug 2012 | B2 |
| 8252051 | Chau et al. | Aug 2012 | B2 |
| 8262724 | Seguin et al. | Sep 2012 | B2 |
| 8273120 | Dolan | Sep 2012 | B2 |
| 8277502 | Miller et al. | Oct 2012 | B2 |
| 8282051 | Nutaro et al. | Oct 2012 | B2 |
| 8287591 | Keidar et al. | Oct 2012 | B2 |
| 8292938 | Case | Oct 2012 | B2 |
| 8308796 | Lashinski et al. | Nov 2012 | B2 |
| 8308798 | Pintor et al. | Nov 2012 | B2 |
| 8317858 | Straubinger et al. | Nov 2012 | B2 |
| 8323332 | Agnew | Dec 2012 | B2 |
| 8323335 | Rowe et al. | Dec 2012 | B2 |
| 8348998 | Pintor et al. | Jan 2013 | B2 |
| 8403983 | Quadri et al. | Mar 2013 | B2 |
| 8449599 | Chau et al. | May 2013 | B2 |
| 8454686 | Alkhatib | Jun 2013 | B2 |
| 8460366 | Rowe | Jun 2013 | B2 |
| 8500798 | Rowe et al. | Aug 2013 | B2 |
| 8512398 | Alkhatib | Aug 2013 | B2 |
| 8512399 | Lafontaine | Aug 2013 | B2 |
| 8568477 | Lashinski et al. | Oct 2013 | B2 |
| 8579964 | Lane et al. | Nov 2013 | B2 |
| 8585755 | Chau et al. | Nov 2013 | B2 |
| 8623080 | Fogarty et al. | Jan 2014 | B2 |
| 8628569 | Benichou et al. | Jan 2014 | B2 |
| 8628571 | Hacohen et al. | Jan 2014 | B1 |
| 8632586 | Spenser et al. | Jan 2014 | B2 |
| 8641757 | Pintor et al. | Feb 2014 | B2 |
| 8652203 | Quadri et al. | Feb 2014 | B2 |
| 8657872 | Seguin | Feb 2014 | B2 |
| 8685085 | Guyenot et al. | Apr 2014 | B2 |
| 8685086 | Navia et al. | Apr 2014 | B2 |
| 8696742 | Pintor et al. | Apr 2014 | B2 |
| 8728155 | Montorfano et al. | May 2014 | B2 |
| 8795355 | Alkhatib | Aug 2014 | B2 |
| 8795356 | Quadri et al. | Aug 2014 | B2 |
| 8808371 | Cartledge | Aug 2014 | B2 |
| 8834564 | Tuval et al. | Sep 2014 | B2 |
| 8840662 | Salahieh et al. | Sep 2014 | B2 |
| 8840663 | Salahieh et al. | Sep 2014 | B2 |
| 8845720 | Conklin | Sep 2014 | B2 |
| 8852272 | Gross et al. | Oct 2014 | B2 |
| 8858620 | Salahieh et al. | Oct 2014 | B2 |
| 8870948 | Erzberger et al. | Oct 2014 | B1 |
| 8870949 | Rowe | Oct 2014 | B2 |
| 8876895 | Tuval et al. | Nov 2014 | B2 |
| 8894702 | Quadri et al. | Nov 2014 | B2 |
| 8911493 | Rowe et al. | Dec 2014 | B2 |
| 8926690 | Kovalsky | Jan 2015 | B2 |
| 8926691 | Chau et al. | Jan 2015 | B2 |
| 8932358 | Nehls | Jan 2015 | B1 |
| 8961595 | Alkhatib | Feb 2015 | B2 |
| 8968395 | Hauser et al. | Mar 2015 | B2 |
| 8986370 | Annest | Mar 2015 | B2 |
| 8986373 | Chau et al. | Mar 2015 | B2 |
| 9005277 | Pintor et al. | Apr 2015 | B2 |
| 9005278 | Pintor et al. | Apr 2015 | B2 |
| 9017399 | Gross et al. | Apr 2015 | B2 |
| 9023100 | Quadri et al. | May 2015 | B2 |
| 9034032 | Mclean et al. | May 2015 | B2 |
| 9034033 | Mclean et al. | May 2015 | B2 |
| 9039757 | Mclean et al. | May 2015 | B2 |
| 9039759 | Alkhatib et al. | May 2015 | B2 |
| 9050188 | Schweich et al. | Jun 2015 | B2 |
| 9066801 | Kovalsky et al. | Jun 2015 | B2 |
| 9072604 | Melnick et al. | Jul 2015 | B1 |
| 9084676 | Chau et al. | Jul 2015 | B2 |
| 9132006 | Spenser et al. | Sep 2015 | B2 |
| 9155617 | Carpentier et al. | Oct 2015 | B2 |
| 9168130 | Straubinger et al. | Oct 2015 | B2 |
| 9168133 | Spenser et al. | Oct 2015 | B2 |
| 9173738 | Murray et al. | Nov 2015 | B2 |
| 9192466 | Kovalsky et al. | Nov 2015 | B2 |
| 9226826 | Rust | Jan 2016 | B2 |
| 9241792 | Benichou et al. | Jan 2016 | B2 |
| 9248016 | Oba et al. | Feb 2016 | B2 |
| 9259315 | Zhou et al. | Feb 2016 | B2 |
| 9265631 | Straubinger et al. | Feb 2016 | B2 |
| 9289293 | Murad et al. | Mar 2016 | B2 |
| 9295547 | Costello et al. | Mar 2016 | B2 |
| 9295548 | Drews et al. | Mar 2016 | B2 |
| 9295550 | Nguyen et al. | Mar 2016 | B2 |
| 9301843 | Richardson et al. | Apr 2016 | B2 |
| 9301863 | Punga et al. | Apr 2016 | B2 |
| 9331328 | Eberhardt et al. | May 2016 | B2 |
| 9339377 | Quadri et al. | May 2016 | B2 |
| 9339378 | Quadri et al. | May 2016 | B2 |
| 9339379 | Quadri et al. | May 2016 | B2 |
| 9339380 | Quadri et al. | May 2016 | B2 |
| 9339382 | Tabor et al. | May 2016 | B2 |
| 9345573 | Nyuli et al. | May 2016 | B2 |
| 9358111 | Spence et al. | Jun 2016 | B2 |
| 9370423 | Ryan | Jun 2016 | B2 |
| 9370424 | Call et al. | Jun 2016 | B2 |
| 9375311 | Gloss et al. | Jun 2016 | B2 |
| 9387071 | Tuval et al. | Jul 2016 | B2 |
| 9402719 | Lane et al. | Aug 2016 | B2 |
| 9402721 | Buchbinder et al. | Aug 2016 | B2 |
| 9414913 | Beith et al. | Aug 2016 | B2 |
| 9414918 | Chau et al. | Aug 2016 | B2 |
| 9433503 | Tsukashima et al. | Sep 2016 | B2 |
| 9439757 | Wallace et al. | Sep 2016 | B2 |
| 9456896 | Quadri et al. | Oct 2016 | B2 |
| 9468525 | Kovalsky | Oct 2016 | B2 |
| 9480556 | Revuelta et al. | Nov 2016 | B2 |
| 9480559 | Vidlund et al. | Nov 2016 | B2 |
| 9486306 | Tegels et al. | Nov 2016 | B2 |
| 9492273 | Wallace et al. | Nov 2016 | B2 |
| 9510946 | Chau et al. | Dec 2016 | B2 |
| 9522062 | Tuval | Dec 2016 | B2 |
| 9532870 | Cooper et al. | Jan 2017 | B2 |
| 9554903 | Rowe et al. | Jan 2017 | B2 |
| 9561100 | Pintor et al. | Feb 2017 | B2 |
| 9561103 | Granada et al. | Feb 2017 | B2 |
| 9572662 | Morriss et al. | Feb 2017 | B2 |
| 9579194 | Elizondo et al. | Feb 2017 | B2 |
| 9579196 | Morriss et al. | Feb 2017 | B2 |
| 9750605 | Ganesan et al. | Sep 2017 | B2 |
| 9750606 | Ganesan et al. | Sep 2017 | B2 |
| 9750607 | Ganesan et al. | Sep 2017 | B2 |
| 9974647 | Ganesan et al. | May 2018 | B2 |
| 10213301 | Ganesan et al. | Feb 2019 | B2 |
| 10265166 | Schweich et al. | Apr 2019 | B2 |
| 10603167 | Ganesan et al. | Mar 2020 | B2 |
| 20010007956 | Letac et al. | Jul 2001 | A1 |
| 20010021872 | Bailey et al. | Sep 2001 | A1 |
| 20020151970 | Garrison et al. | Oct 2002 | A1 |
| 20030055492 | Shaolian et al. | Mar 2003 | A1 |
| 20030130726 | Thorpe et al. | Jul 2003 | A1 |
| 20040127982 | Machold et al. | Jul 2004 | A1 |
| 20040210307 | Khairkhahan | Oct 2004 | A1 |
| 20040260393 | Rahdert et al. | Dec 2004 | A1 |
| 20050010287 | Macoviak et al. | Jan 2005 | A1 |
| 20050049697 | Sievers | Mar 2005 | A1 |
| 20050137689 | Salahieh et al. | Jun 2005 | A1 |
| 20050137690 | Salahieh et al. | Jun 2005 | A1 |
| 20050165479 | Drews et al. | Jul 2005 | A1 |
| 20060235509 | Lafontaine | Oct 2006 | A1 |
| 20070027533 | Douk | Feb 2007 | A1 |
| 20070100440 | Figulla et al. | May 2007 | A1 |
| 20070168024 | Khairkhahan | Jul 2007 | A1 |
| 20080004697 | Lichtenstein et al. | Jan 2008 | A1 |
| 20080015671 | Bonhoeffer | Jan 2008 | A1 |
| 20080086164 | Rowe | Apr 2008 | A1 |
| 20080103586 | Styrc et al. | May 2008 | A1 |
| 20080140189 | Nguyen et al. | Jun 2008 | A1 |
| 20080183273 | Mesana et al. | Jul 2008 | A1 |
| 20080208327 | Rowe | Aug 2008 | A1 |
| 20080221672 | Lamphere et al. | Sep 2008 | A1 |
| 20090005863 | Goetz et al. | Jan 2009 | A1 |
| 20090216310 | Straubinger et al. | Aug 2009 | A1 |
| 20090216312 | Straubinger et al. | Aug 2009 | A1 |
| 20100049315 | Kirson | Feb 2010 | A1 |
| 20100100173 | Lafontaine | Apr 2010 | A1 |
| 20100131056 | Lapeyre | May 2010 | A1 |
| 20100145440 | Keraenen | Jun 2010 | A1 |
| 20100161036 | Pintor et al. | Jun 2010 | A1 |
| 20100217382 | Chau et al. | Aug 2010 | A1 |
| 20100249894 | Oba et al. | Sep 2010 | A1 |
| 20100249908 | Chau et al. | Sep 2010 | A1 |
| 20100262232 | Annest | Oct 2010 | A1 |
| 20100280606 | Naor | Nov 2010 | A1 |
| 20100298931 | Quadri et al. | Nov 2010 | A1 |
| 20100312333 | Navia et al. | Dec 2010 | A1 |
| 20100331972 | Pintor et al. | Dec 2010 | A1 |
| 20110004296 | Lutter et al. | Jan 2011 | A1 |
| 20110022168 | Cartledge | Jan 2011 | A1 |
| 20110040374 | Goetz et al. | Feb 2011 | A1 |
| 20110137397 | Chau et al. | Jun 2011 | A1 |
| 20110137410 | Hacohen | Jun 2011 | A1 |
| 20110166636 | Rowe | Jul 2011 | A1 |
| 20110208293 | Tabor | Aug 2011 | A1 |
| 20110218619 | Benichou et al. | Sep 2011 | A1 |
| 20110224785 | Hacohen | Sep 2011 | A1 |
| 20110245911 | Quill et al. | Oct 2011 | A1 |
| 20110257721 | Tabor | Oct 2011 | A1 |
| 20110282438 | Drews et al. | Nov 2011 | A1 |
| 20110295363 | Girard et al. | Dec 2011 | A1 |
| 20110301702 | Rust et al. | Dec 2011 | A1 |
| 20110319988 | Schankereli et al. | Dec 2011 | A1 |
| 20110319989 | Lane et al. | Dec 2011 | A1 |
| 20120010697 | Shin et al. | Jan 2012 | A1 |
| 20120016464 | Seguin | Jan 2012 | A1 |
| 20120022639 | Hacohen et al. | Jan 2012 | A1 |
| 20120035722 | Tuval | Feb 2012 | A1 |
| 20120053675 | Borck | Mar 2012 | A1 |
| 20120059458 | Buchbinder et al. | Mar 2012 | A1 |
| 20120078357 | Conklin | Mar 2012 | A1 |
| 20120101571 | Thambar et al. | Apr 2012 | A1 |
| 20120136430 | Sochman et al. | May 2012 | A1 |
| 20120165930 | Gifford et al. | Jun 2012 | A1 |
| 20120310328 | Olson et al. | Dec 2012 | A1 |
| 20130053949 | Pintor et al. | Feb 2013 | A1 |
| 20130079869 | Straubinger et al. | Mar 2013 | A1 |
| 20130090725 | Pintor et al. | Apr 2013 | A1 |
| 20130116777 | Pintor et al. | May 2013 | A1 |
| 20130172992 | Gross et al. | Jul 2013 | A1 |
| 20130184811 | Rowe et al. | Jul 2013 | A1 |
| 20130211508 | Lane et al. | Aug 2013 | A1 |
| 20130282110 | Schweich et al. | Oct 2013 | A1 |
| 20130282114 | Schweich et al. | Oct 2013 | A1 |
| 20130304200 | Mclean et al. | Nov 2013 | A1 |
| 20130345799 | Lafontaine | Dec 2013 | A1 |
| 20140005778 | Buchbinder et al. | Jan 2014 | A1 |
| 20140012372 | Chau et al. | Jan 2014 | A1 |
| 20140012373 | Chau et al. | Jan 2014 | A1 |
| 20140039611 | Lane et al. | Feb 2014 | A1 |
| 20140052237 | Lane et al. | Feb 2014 | A1 |
| 20140200662 | Eftel et al. | Jul 2014 | A1 |
| 20140214156 | Navia et al. | Jul 2014 | A1 |
| 20140222136 | Geist et al. | Aug 2014 | A1 |
| 20140228946 | Chau et al. | Aug 2014 | A1 |
| 20140236291 | Schweich et al. | Aug 2014 | A1 |
| 20140257467 | Lane et al. | Sep 2014 | A1 |
| 20140316516 | Vidlund et al. | Oct 2014 | A1 |
| 20140343669 | Lane et al. | Nov 2014 | A1 |
| 20140358223 | Rafiee et al. | Dec 2014 | A1 |
| 20140364943 | Conklin | Dec 2014 | A1 |
| 20150039083 | Rafiee | Feb 2015 | A1 |
| 20150094802 | Buchbinder et al. | Apr 2015 | A1 |
| 20150112433 | Schweich et al. | Apr 2015 | A1 |
| 20150127096 | Rowe et al. | May 2015 | A1 |
| 20150142103 | Vidlund | May 2015 | A1 |
| 20150150678 | Brecker | Jun 2015 | A1 |
| 20150157458 | Thambar et al. | Jun 2015 | A1 |
| 20150173897 | Raanani et al. | Jun 2015 | A1 |
| 20150196390 | Ma et al. | Jul 2015 | A1 |
| 20150216656 | Pintor et al. | Aug 2015 | A1 |
| 20150216657 | Braido | Aug 2015 | A1 |
| 20150216660 | Pintor et al. | Aug 2015 | A1 |
| 20150238312 | Lashinski | Aug 2015 | A1 |
| 20150238313 | Spence et al. | Aug 2015 | A1 |
| 20150265402 | Centola et al. | Sep 2015 | A1 |
| 20150320553 | Chau et al. | Nov 2015 | A1 |
| 20150327995 | Morin et al. | Nov 2015 | A1 |
| 20150327996 | Fahim et al. | Nov 2015 | A1 |
| 20150327999 | Board et al. | Nov 2015 | A1 |
| 20150335421 | Figulla et al. | Nov 2015 | A1 |
| 20150342733 | Alkhatib et al. | Dec 2015 | A1 |
| 20150351906 | Hammer et al. | Dec 2015 | A1 |
| 20150359629 | Ganesan et al. | Dec 2015 | A1 |
| 20160000564 | Buchbinder et al. | Jan 2016 | A1 |
| 20160008131 | Christianson et al. | Jan 2016 | A1 |
| 20160022417 | Karapetian et al. | Jan 2016 | A1 |
| 20160045307 | Yohanan et al. | Feb 2016 | A1 |
| 20160045309 | Valdez et al. | Feb 2016 | A1 |
| 20160051362 | Cooper et al. | Feb 2016 | A1 |
| 20160074160 | Christianson et al. | Mar 2016 | A1 |
| 20160106539 | Buchbinder et al. | Apr 2016 | A1 |
| 20160113768 | Ganesan et al. | Apr 2016 | A1 |
| 20160120646 | Dwork et al. | May 2016 | A1 |
| 20160158000 | Granada et al. | Jun 2016 | A1 |
| 20160158001 | Wallace et al. | Jun 2016 | A1 |
| 20160158003 | Wallace et al. | Jun 2016 | A1 |
| 20160184095 | Spence et al. | Jun 2016 | A1 |
| 20160193044 | Achiluzzi | Jul 2016 | A1 |
| 20160199180 | Zeng et al. | Jul 2016 | A1 |
| 20160220364 | Straubinger et al. | Aug 2016 | A1 |
| 20160228251 | Nyuli et al. | Aug 2016 | A1 |
| 20160235529 | Ma et al. | Aug 2016 | A1 |
| 20160242906 | Morriss et al. | Aug 2016 | A1 |
| 20160270911 | Ganesan et al. | Sep 2016 | A1 |
| 20160270917 | Tuval et al. | Sep 2016 | A1 |
| 20160310268 | Oba et al. | Oct 2016 | A1 |
| 20160317290 | Chau et al. | Nov 2016 | A1 |
| 20160317304 | Spence et al. | Nov 2016 | A1 |
| 20160324631 | Lane et al. | Nov 2016 | A1 |
| 20160324633 | Gross et al. | Nov 2016 | A1 |
| 20160331523 | Chau et al. | Nov 2016 | A1 |
| 20160331531 | Quadri et al. | Nov 2016 | A1 |
| 20160331534 | Buchbinder et al. | Nov 2016 | A1 |
| 20160338826 | Chau et al. | Nov 2016 | A1 |
| 20160338829 | Call et al. | Nov 2016 | A1 |
| 20160346080 | Righini et al. | Dec 2016 | A1 |
| 20160354203 | Tuval et al. | Dec 2016 | A1 |
| 20160354204 | Braido et al. | Dec 2016 | A1 |
| 20160361162 | Richter et al. | Dec 2016 | A1 |
| 20160361163 | Yohanan et al. | Dec 2016 | A1 |
| 20160374801 | Jimenez et al. | Dec 2016 | A1 |
| 20170007398 | Drews et al. | Jan 2017 | A1 |
| 20170049564 | Board et al. | Feb 2017 | A1 |
| 20170056162 | Harewood | Mar 2017 | A1 |
| 20170056163 | Tayeb et al. | Mar 2017 | A1 |
| 20170056166 | Ratz et al. | Mar 2017 | A1 |
| 20170056176 | Rowe et al. | Mar 2017 | A1 |
| 20180000586 | Ganesan et al. | Jan 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 0350302 | Jan 1990 | EP |
| 0592410 | Oct 1995 | EP |
| 0705081 | Oct 2001 | EP |
| 1338255 | Aug 2003 | EP |
| 0825841 | Oct 2003 | EP |
| 0833595 | Oct 2003 | EP |
| 0910313 | Nov 2003 | EP |
| 0910314 | Nov 2003 | EP |
| 1006949 | Oct 2004 | EP |
| 1233731 | Dec 2004 | EP |
| 1251803 | Jun 2005 | EP |
| 1267753 | Oct 2005 | EP |
| 0830112 | Nov 2005 | EP |
| 1171059 | Nov 2005 | EP |
| 1328215 | Nov 2005 | EP |
| 1603493 | Dec 2005 | EP |
| 1621162 | Feb 2006 | EP |
| 1318775 | Nov 2006 | EP |
| 1474077 | Feb 2007 | EP |
| 1143882 | Dec 2007 | EP |
| 1180987 | Aug 2008 | EP |
| 1237509 | Dec 2008 | EP |
| 1562522 | Dec 2008 | EP |
| 2000115 | Dec 2008 | EP |
| 1330213 | Mar 2009 | EP |
| 1610727 | Apr 2009 | EP |
| 2055266 | May 2009 | EP |
| 1343438 | Jul 2009 | EP |
| 2078498 | Jul 2009 | EP |
| 1684667 | Aug 2009 | EP |
| 1408850 | Sep 2009 | EP |
| 1653888 | Sep 2009 | EP |
| 1049425 | Nov 2009 | EP |
| 2138132 | Dec 2009 | EP |
| 1703865 | Feb 2010 | EP |
| 1682048 | Mar 2010 | EP |
| 1509171 | Jun 2010 | EP |
| 1968491 | Jul 2010 | EP |
| 1176913 | Oct 2010 | EP |
| 1465554 | Dec 2010 | EP |
| 1940321 | Dec 2010 | EP |
| 2258312 | Dec 2010 | EP |
| 2258316 | Dec 2010 | EP |
| 2260796 | Dec 2010 | EP |
| 2260797 | Dec 2010 | EP |
| 2260798 | Dec 2010 | EP |
| 2263609 | Dec 2010 | EP |
| 2316381 | May 2011 | EP |
| 1441672 | Sep 2011 | EP |
| 2160150 | Oct 2011 | EP |
| 2399549 | Dec 2011 | EP |
| 2399550 | Dec 2011 | EP |
| 1788984 | Feb 2012 | EP |
| 2420205 | Feb 2012 | EP |
| 2476394 | Jul 2012 | EP |
| 2124824 | Oct 2012 | EP |
| 2088965 | Nov 2012 | EP |
| 2526895 | Nov 2012 | EP |
| 2526898 | Nov 2012 | EP |
| 2526899 | Nov 2012 | EP |
| 2529696 | Dec 2012 | EP |
| 2529697 | Dec 2012 | EP |
| 2529698 | Dec 2012 | EP |
| 2529699 | Dec 2012 | EP |
| 2537487 | Dec 2012 | EP |
| 1919397 | Jan 2013 | EP |
| 2015709 | Jan 2013 | EP |
| 1750622 | Feb 2013 | EP |
| 2257242 | Feb 2013 | EP |
| 1701668 | Mar 2013 | EP |
| 2340075 | Mar 2013 | EP |
| 2572675 | Mar 2013 | EP |
| 2572676 | Mar 2013 | EP |
| 2262447 | Aug 2013 | EP |
| 2626040 | Aug 2013 | EP |
| 2626041 | Aug 2013 | EP |
| 1758523 | Sep 2013 | EP |
| 2073756 | Oct 2013 | EP |
| 2109417 | Nov 2013 | EP |
| 2477555 | Dec 2013 | EP |
| 2674130 | Dec 2013 | EP |
| 1838241 | Feb 2014 | EP |
| 1926455 | Apr 2014 | EP |
| 2405966 | Apr 2014 | EP |
| 2257243 | May 2014 | EP |
| 2745805 | Jun 2014 | EP |
| 2117469 | Jul 2014 | EP |
| 2124826 | Jul 2014 | EP |
| 2749254 | Jul 2014 | EP |
| 1667604 | Aug 2014 | EP |
| 2211779 | Aug 2014 | EP |
| 2772228 | Sep 2014 | EP |
| 2142143 | Nov 2014 | EP |
| 2815723 | Dec 2014 | EP |
| 2815724 | Dec 2014 | EP |
| 2815725 | Dec 2014 | EP |
| 2254515 | Jan 2015 | EP |
| 1465555 | May 2015 | EP |
| 2068767 | Jul 2015 | EP |
| 1702247 | Aug 2015 | EP |
| 1729688 | Aug 2015 | EP |
| 2901966 | Aug 2015 | EP |
| 1804686 | Sep 2015 | EP |
| 2675396 | Sep 2015 | EP |
| 1734903 | Oct 2015 | EP |
| 2254513 | Oct 2015 | EP |
| 2544626 | Oct 2015 | EP |
| 2926766 | Oct 2015 | EP |
| 2926767 | Oct 2015 | EP |
| 1748745 | Dec 2015 | EP |
| 1755459 | Dec 2015 | EP |
| 1850796 | Dec 2015 | EP |
| 1991168 | Jan 2016 | EP |
| 2254512 | Jan 2016 | EP |
| 2012712 | Feb 2016 | EP |
| 1585463 | Mar 2016 | EP |
| 2170416 | Mar 2016 | EP |
| 2278944 | Mar 2016 | EP |
| 1871300 | Apr 2016 | EP |
| 2237746 | May 2016 | EP |
| 2582326 | May 2016 | EP |
| 2618784 | May 2016 | EP |
| 1734902 | Jun 2016 | EP |
| 1906884 | Jun 2016 | EP |
| 2190379 | Jun 2016 | EP |
| 2416739 | Jun 2016 | EP |
| 2007-516055 | Jun 2007 | JP |
| 2004082527 | Sep 2004 | WO |
| 2005062980 | Jul 2005 | WO |
| 2009155561 | Dec 2009 | WO |
| 2011109813 | Sep 2011 | WO |
| 2011119101 | Sep 2011 | WO |
| 2012103204 | Aug 2012 | WO |
| 2016065158 | Apr 2016 | WO |
| Entry |
|---|
| US 9,532,869 B2, 01/2017, Quadri et al. (withdrawn) |
| European Search Report in European Application No. 15170546.4, dated Apr. 12, 2016, 7 pages. |
| International Search Report and Written Opinion in International Application No. PCT/US2015/056935, dated Feb. 12, 2016, 13 pages. |
| Office Action received for European Patent Application No. 15170546.4, dated Jun. 3, 2019, 3 pages. |
| Supplementary European Search Report in Eurpoean Application No. 13778768, dated Jan. 12, 2016, 7 pages. |
| U.S. Appl. filed Dec. 16, 2009, Chau et al., U.S. Appl. No. 61/266,774. |
| U.S. Appl. filed Dec. 4, 2009, Chau et al., U.S. Appl. No. 61/287,099. |
| US 9,532,869, 1/2017, Quadri et al. (withdrawn). |
| Number | Date | Country | |
|---|---|---|---|
| 20200205977 A1 | Jul 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62067907 | Oct 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15685596 | Aug 2017 | US |
| Child | 16801004 | US | |
| Parent | 14674349 | Mar 2015 | US |
| Child | 15685596 | US | |
| Parent | 14673055 | Mar 2015 | US |
| Child | 14674349 | US | |
| Parent | 14671577 | Mar 2015 | US |
| Child | 14673055 | US |
